Pipequaline

    • Catalog No.:MC1376
      • CasNo:
      • 77472-98-1
      • MolecularFormula:
      • C22H24N2
      • Purity:
      • >98%
      • Target:
      • GABA Receptor
      • IC50:
      • No data
      • In Vitro:
      • Pipequaline is extensively bound to plasma proteins: i.e. human serum albumin (HSA), alpha-1-acid glycoprotein (AAG), lipoproteins and blood cells, mainly erythrocytes[1].
      • In Vivo:
      • Intravenously administered pipequaline exerts a partial suppression of activations by kainate, glutamate and acetylcholine. Microiontophoretic applications of pipequaline reduces the neuronal activation by kainate[2]. Pipequaline produces dose-related decreases in motor activity. Pipequaline produces significant dose-related decreases in the number of head-dips made[3].
      • Fields:
      • Pipequaline (PK 8165) is a partial benzodiazepine receptor agonist with anxiolytic activity.
      • Specificity:
      • Target: GABA Receptor. Fields: Pipequaline (PK 8165) is a partial benzodiazepine receptor agonist with anxiolytic activity.
      • Concentration:
      • >98%
      • Storage Stability:
      • 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
      • Other Name:
      • PK-8165; PK8165; PK 8165
      • MolecularWeight(Da):
      • 316.44
      • References:
      • [1]. Essassi D, et al. Pipequaline transport from blood to brain and liver: role of plasma protein-bound drug. J Pharm Pharmacol. 1989 Sep;41(9):595-600. [2]. Debonnel G, et al. Pipequaline acts as a
      • Products Images